21 Cousin M, Chiriac A, Molinari N, Demoly P, Caimmi D. 22 23 Phenotypical characterization of children with hypersensitivity reactions to NSAIDs 24 Pediatr Allergy Immunol 25 26 Background. Non-steroidal anti-inflammatory drugs (NSAIDs) are the main cause of drug-induced 27 hypersensitivity in children. Many classifications have been proposed, focusing on adults. So far, no 28 large study has deeply investigated a pediatric cohort. The aim of the present study was to describe 29 a population of NSAID hypersensitive patients reporting a reaction during their childhood, and to 30 verify if it is possible to classify pediatric patients, following the EAACI/ENDA classification. 31 Methods. We conducted a historical-prospective study including patients evaluated from 1996 to 32 2015 in the allergy unit of the Montpellier University Hospital. We included 635 patients. For each 33 patient, we recorded clinical manifestations and possible co-morbidities, and tried to identify 34 possible risk factors. 35 Results. NSAIDs hypersensitivity was diagnosed in 107 out of 635 patients (16.9%). In this group, 36 43 patients (40.2%) could not be classified following the ENDA recommendations. The main 37 discrepancies were on the patients' clinical manifestations and on their possible underlying diseases. 38 We identified, on a multivariate analysis, some risk factors for NSAID hypersensitivity: chronic 39 urticaria (OR 7.737, 3.375-18.296 95%CI), atopic status (OR 2.514, 1.504-4.364 95%CI) and 40 allergic rhino-conjunctivitis (OR 1.799, 1.138-2.837 95%CI). On the basis of our results, we are 41 proposing an adapted classification for NSAIDs hypersensitivity in children. 42 Conclusions. The current ENDA classification does not seem to be adapted for pediatric patients; a 43 modified version does. Our study could help allergists better understand the differences between 44 adults and children in developing hypersensitivity reactions to NSAIDs but further large-scale 45 prospective longitudinal analyses are required to validate this new classification. 46 47
Introduction 51
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat fever and pain in 52 children. Nevertheless, they are currently considered as the first cause of drug-induced 53 hypersensitivity (HS) reactions in children (1, 2) . Two different mechanisms are able to elicit HS 54 reactions: immunological mechanisms responsible for allergic HS reactions (such as IgE and T-cells 55 mediated reactions); and non-immunologic ones (mainly due to cyclooxygenases inhibition). 56
Several classifications have been proposed for NSAIDs HS, but no large study has so far tried to 57 classify NSAIDs HS focusing only on a pediatric population. 58
In 2001, Stevenson classified patients according to their clinical history but this classification did 59 not take into account the reactions recorded during drug provocation tests (DPTs) (3). Thereafter, 60
Quiralte proposed a classification with seven groups according to the patient's underlying disease 61
(4). The most recent NSAIDs HS classification highlighted five groups of patients, and has been 62 published by the European Network for Drug Allergy (ENDA) group, an EAACI drug allergy 63
Interest Group (5). This classification was based on the authors' expertise in hypersensitivity 64 reactions to NSAIDs. The publication does not differentiate between age groups, and it has to be 65 underlined that most of the expertise comes from adolescents and adults. Since its publication, 66 clinical observations and literature data (6) reported that some patients diagnosed with NSAIDs HS 67 could not be classified into the possible phenotypes described by the ENDA group (5). Moreover, 68 while the Widal's syndrome (or Samter's triad) is used as a reference phenotype for the first group 69 of the ENDA classification, "NSAID's-exacerbated respiratory disease", it is known that such a 70 syndrome has never been described before the age of 13 (7). In addition, a recent paper (1) reported 71 that the association of cutaneous and respiratory symptoms is frequently observed in children with 72
NSAIDs HS, which is a combination of different phenotypes proposed by the current classification, 73 but is not highlighted as a single group. 74
Considering the hypothesis that HS phenotypes may differ between the adult and pediatric 75 population, the aim of the present study was to describe a population of children with a diagnosis of 76 4 NSAIDs HS, and to try to classify them on the basis of the current ENDA recommendation. We also 77 tried to identify possible risk factors for NSAIDs HS in children, and to propose a pediatric version 78 of the ENDA classification. was defined as a rapid allergic response involving two different organs with or without associated 116 hypotension (11). Laryngeal angioedema associated dyspnea was considered as a muco-cutaneous 117
symptom. 118
We tested children with the culprit drug and, in case of a positive DPT, patients were tested, at least 119 4 weeks after the previous DPT, with a different NSAID, belonging to another chemical subgroup. 120
All together, 14 different NSAIDs have been tested, belonging to different chemical subgroups: 121 acetylsalicylic acid, celocoxib, diclofenac, etoricoxib, ibuprofen, ketoprofen, meloxicam, 122 metamizole, niflumic acid, nimesulide, piroxicam, trofecoxib, tiaprofenic acid. 123
Paracetamol/acetaminophen was included as well in the list of the 14 tested drugs. 124 125
Patients' classification 126
In order to evaluate the accuracy of the ENDA classification (Table 1) in our pediatric cohort, we 127 tried to attribute each patient to the different ENDA groups, numbered from 1 to 5: Whenever a phenotype did not strictly correspond to one of the 5 groups, the patient was classified 134 as "divergent" according to the following criteria: 135 -the patient was included in the group that seemed the closest to his phenotype; 136 -we used a letter to highlight for which feature of the group the patient did not properly fit in 137 the ENDA classification: Aclinical manifestations; Bdelay of the reaction; C -138 underlying disease; Dcross-reactivity (for example, an asthmatic patient who developed 139 urticaria to several NSAIDs was classified as 3C); 140 -a patient divergent for more than one feature of the group was considered as "not possible to 141 classify". 142 143
Statistical analysis 144
Categorical data were expressed in frequencies and percent, continuous data in median and 145 quartiles. To evaluate possible risk factors, we analyzed crude and adjusted odds ration, with a 95% 146 confidence interval. A multivariate analysis was conducted using a logistic regression model to 147 determine independent risk factors of NSAIDs, in which we included all variables associated with a 148 p value below 0.20 in the univariate analysis. Then, a stepwise procedure allowed obtaining the 149 final multivariate model. We considered as statistically significant a p-value < 0.05. 150 151 152
Results 153
Patients' characteristics, DPT and symptoms 7 635 patients fulfilled our inclusion criteria. In 107 out of 635 (16.9%) a reaction was recorded 155 through the DPT, and a diagnosis of NSAIDs HS was reached. 62 out of 107 patients were female 156 (57.9%). The characteristics of the age distribution of our patients are shown in Table 2 . 157
In the group of the 107 diagnosed patients, 77 (72.0%) were atopic and 47 (43.9%) were sensitized 158 to house dust mites. We are missing these data in 8 patients, that were therefore considered as non-159 atopic nor sensitized to mites. Also, 19 patients (17.8%) suffered from chronic urticaria, 45 (42.1%) 160 reported symptoms of allergic rhino-conjunctivitis, and 37 (34.6%) were asthmatic. Two of the 161 asthmatic patients, who were nevertheless adults at the time of their first DPT, presented with nasal 162 polyposis as well. Other allergic diseases included atopic dermatitis (7 patients, 6.5%), food allergy 163 Among the 107 patients with NSAIDs HS, 43 patients (40.2%) could not be completely classified in 181 the current ENDA classification and were divergent for one criterion, while 4 patients (3.7%) were 182 considered as "not possible to classify" (divergent for more than one criterion), as shown in Table 3 . 183
Patients were divergent mainly for the feature A, "clinical manifestation" and C, "underlying 184 disease". No patient was divergent for the feature B, "delay of reaction". No patient strictly 185 corresponded to the group 1, "NSAIDs-exacerbated respiratory disease" of the ENDA classification 186 (Table 3) . 187
Among the 22 patients belonging to the group 4, "single-NSAID-induced urticaria/angioedema or 188 anaphylaxis", the main culprit drugs were paracetamol/acetaminophen (7 patients, 31.8% of the 189 group) and ibuprofene (7 patients, 31.8% of the group). All these patients had a negative DPT to at 190 least one other NSAID. The rest of the results are shown in Table 3 . 191
192

New possible pediatric classification 193
On the basis of our results, we proposed a new classification in three groups, strictly derived from 194 the ENDA one. This classification remains focused on the pathophysiologic HS mechanism, but we 195 also included, as a feature, the impact of risk factors (urticarial, atopy, allergic rhino-conjunctivitis, 196 and age at first reaction). We excluded the presence of underlying diseases (which could occur later 197 in life), and modified the possible clinical manifestations (Table 4) . 198
In this new classification, all our patients could be classified and no patient was divergent. We 199 included 91 patients (85.1%) in the group I, "non-allergic NSAIDs hypersensitivity", 15 patients 200 (14.0%) in the group II, "single NSAID-induced urticarial/angioedema/anaphylaxis", and 1 patient 201 (0.9%) in the group III, "single NSAID-induced delayed reactions". The group I contains actually 202 groups 1 through 3 of the ENDA classification, and it has to be considered as a transitory group, 203 since patients may develop underlying chronic diseases throughout age. Even though a recent paper 204 did not highlight a correlation between NSAID-induced urticaria and evolution toward chronic 205 urticaria (12), these data refer to adult patients over a 12-years follow-up, and might differ from 206 9 what we might record in a strictly pediatric population. Therefore, so far, the evolution of the 207 immune system and the possible appearance of chronic diseases seem not to allow, in children, a 208 differentiation between the first 3 ENDA groups. 209 210 211
Discussion 212
Drug hypersensitivity is acquiring more and more importance in patients' everyday life. The 213 EAACI and the ENDA group in particular have proposed several protocols and tools to guide 214 allergists to perform a correct diagnosis and a complete allergy work-up in patients presenting with 215 a suspected hypersensitivity reaction to drugs. As for NSAIDs, a classification has been proposed in 216 2013, but it focused on adult populations. The fact that it is now clear that NSAIDs HS is a key 217 issue in the pediatric population as well, made it imperative to evaluate the appropriateness of such 218 a classification in this group of patients. 219
To our knowledge, we described the largest pediatric cohort with a diagnosis of NSAIDs 220 hypersensitivity. The first aspect highlighted by our results is that the ENDA classification did not 221 allow us to classify more than 40% of the patients, and it seems therefore clear that the current 222 recommendations are not suitable for the pediatric population. 223
According to a recent pediatric study by Cavkaytar et al. (13) , who analyzed a cohort of 30 NSAIDs 224 hypersensitive patients, phenotypes are different in children and adults and pediatric subjects cannot 225 completely be classified in the latest classifications (5, 6). In the same study, 27% of patients were 226 diagnosed as NSAID hypersensitive and only one patient was classified in the group "NSAIDs-227 exacerbated respiratory disease" of ENDA classification (13). Our results are similar to those 228 highlighted by Cavkaytar et al: in fact, the main problem we found in our cohort was related to the 229 first group proposed by ENDA, "NSAIDs-exacerbated respiratory disease", since none of our 230 patients could perfectly fit in this group. Indeed, this group was initially created for adults suffering 231 from late onset asthma, which is frequently associated with chronic rhino-sinusitis and nasal 232 polyposis and with a possible progression towards severe asthma (recurrent respiratory 233 exacerbations and corticosteroid-dependence) (14, 15) . 234
Considering that NSAIDs HS, and drug HS in general, tends to persist over the years, we could 235 speculate that the evolution of children's immune system and the possible appearance of new and 236 persistent underlying diseases make it difficult to include patients in this group, even though the 237 same patients may belong to it once grown. Nevertheless, in a pediatric classification, it seems 238 inappropriate to classify children according to their underlying disease. 239
An interesting aspect of our results is that most of our patients (97.2%) reacted to NSAIDs 240 presenting urticaria and/or angioedema as a symptom. Therefore, mucocutaneous symptoms are not 241 specific during the pediatric age and not sufficient to differentiate and classify patients. Also, only 242 very few patients (1.9%) presented isolated bronchospasm as a symptom, and such a result is 243 confirmed by other authors (2, 16). 244
In the literature, physical exercise is often considered as a risk factor to develop an HS reaction to 245 NSAIDs; also, NSAIDs are known as a potential trigger for developing food allergy reactions (1) . 246
However, recent NSAIDs HS classification did not include these risk factors. We did not find a 247 correlation between food allergy and NSAIDs HS, and we did not have patients who presented a 248 pediatric clinical history in which physical exercise was related to the appearance of HS symptoms 249 after NSAID intake (data not shown). In the literature, a significant association has been found 250 between house dust mites' sensitization and NASIDs hypersensitivity (14). In our study, atopy (but 251 not particularly house dust mites sensitization), urticaria, allergic rhino-conjunctivitis, and an early 252 reaction in life were found as significant risk factors for hypersensitivity reactions to NSAIDs. 253
Taking into account all of these considerations, we proposed a new classification for NSAIDs HS in 254 children, in which we included the presence of the previously mentioned risk factors, and we 255 neglected the presence of possible underlying chronic diseases. This classification could actually be 256 a helpful tool to understand the mechanisms leading to the HS reaction and to guide allergists in 257 their work-up. 258 11 A limitation of this study was that we didn't perform any skin test for the patients who presented 259 anaphylactic reaction or reaction to a single NSAID in their clinical history. Such data could help 260 proving the possible IgE mediated mechanism. Nevertheless, skin tests are not standardized nor 261 validated in clinical practice for NSAIDs and, more importantly, we preferred to use DPT as the 262 gold standard to reach a diagnose of hypersensitivity reaction. Also, we did not test many patients 263 with aspirin. This is due to the fact that such a drug is rarely prescribed in children, due to the risk 264 of Reye's syndrome, and, therefore, a clinical approach to NSAIDs hypersensitivity in children 265 cannot focus on such molecule, which, on the other hand, is often administered in the adult 266 population. Another possible limitation of the present study concerns the diagnosis of rhino-sinusitis 267 and nasal polyposis. Indeed, these diagnoses are mostly done in adult patients and require 268 endoscopic and/or imaging techniques. Therefore, we could not exclude an underestimation of these 269 diseases, even though, at least for nasal polyposis, such a diagnosis is rare during childhood and 270 generally related to other diseases. 271
In conclusion, during childhood every child is exposed at least once to a NSAID, and there are no 272 alternative, on a routine base, to treat fever and/or pain. An accurate classification of NSAIDs 273 hypersensitive patients could help better understand the pathology of these reactions and guide the 274 management of these patients since their early age. We believe that our study could help allergists 275 better understand the differences between adults and children in developing HS reactions to 276 NSAIDs and could indicate a possible way to modify the present classification. 277
